Data from 2 patient cohorts show that by increasing awareness of such influences as clinic location and patient age and transgender status, gaps in prescription decisions for integrase strand transfer inhibitors (INSTIs) can be lessened.
A new examination of 9558 persons living with HIV in Washington, DC, and Baltimore, MD, shows that despite HHS’ recommendation of integrase strand transfer inhibitors (INSTIs) as initial antiretroviral therapy (ART) for most patients, certain factors continue to influence clinician decision-making.
Findings from a study that looked at data from the Johns Hopkins HIV Clinical Cohort—for patients receiving their HIV care at the John G. Bartlett Specialty Practice at Johns Hopkins Medicine—and the DC Cohort—for patients receiving care at 15 clinics in Washington, DC—in particular show that patient age, whether they are transgender, and their clinic location may lead to INSTI prescribing disparities that are rooted in nonclinical reasons.
These results appeared in a recent issue of Open Forum Infectious Diseases.
“If disparities exist, they may be detrimental in terms of overall HIV outcomes because INSTIs are favored due to their potency and tolerability,” the authors wrote. “Our objective was to describe INSTI prescribing prevalence and examine disparities in INSTI prescribing in 2 different locations in the Mid-Atlantic States area.”
Among the study participants—all of whom had at least 1 HIV clinic visit from April 1, 2017, to March 31, 2019, and had been prescribed ART prior to that—most were aged 50 and older, a cisgender male having sex with another man, and non-Hispanic Black, with public insurance coverage. The investigators found that among the entire study cohort (n = 6839 currently taking an INSTI; n = 754 previously on an INSTI; n = 1965 never prescribed an INSTI), 79.4% had ever been prescribed an INSTI, and that of this group, 71.5% had a current prescription (dolutegravir, 47.9%; elvitegravir, 27.7%, bictegravir, 16.8%; raltegravir, 7.5%) and 7.9% had a previous prescription.
The investigators analysis produced these results:
Adjusting for covariates, the authors also found a 97% greater chance of being prescribed an INSTI from receiving care at Hopkins vs in DC (adjusted odds ratio [aOR], 1.97; 95% CI, 1.69-2.29) and a 115% greater likelihood of being a younger age (aOR, 2.15; 95% CI, 1.42-3.26). Alcohol use disorder and having mutations resistant to nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs were also associated with greater odds of having a current/previous INSTI prescription, at 29%, 85%, and 50%, respectively.
The odds of ever being prescribed an INSTI markedly dropped, however, if patients were transgender women (aOR, 0.62; 95% CI, 0.43-0.89) or had a longer HIV duration (aOR, 0.98 per 5-year increase; 95% CI, 0.97-0.99).
The authors wrote that their findings “uniquely add to the HIV medical literature” because they demonstrate INSTI use disparities, particularly on the part of transgender women and their clinicians who may express hesitation toward newer ART agents due to possible interactions with hormones. Transgender women also have a greater chance of facing health care–related discrimination, so they have poor care retention and a lesser likelihood of being virally suppressed, the authors noted.
“Identifying disparities may allow clinicians to focus their attention on these individuals,” they concluded, “and ensure that therapy decisions are grounded in valid clinical reasons.”
Reference
Monroe AK, Levy M, Greenberg AE, et al. Integrase inhibitor prescribing disparities in the DC and Johns Hopkins HIV Cohorts. Open Forum Infect Dis. 2021;8(8):1-5. doi:10.1093/ofid/ofab338
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More